Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -43906.17% is 40% below its 5-year average of -31311.91%, around the middle of its 5-year range (-87100.00%–-9047.97%).
25.18% above its 12-month average of -58684.18%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -32806.67%.
EBITDA MARGIN
-43906.17%
EBITDA MARGIN AVG TTM
-58684.18%
EBITDA MARGIN AVG 3Y
-39304.63%
EBITDA MARGIN AVG 5Y
-31311.91%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+25.18%
CURRENT VS 3Y AVG
-11.71%
CURRENT VS 5Y AVG
-40.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Sera Prognostics, Inc.
Market Cap
$77.15M
EBITDA Margin
-43906.17%
TTM Avg
-58684.18%
3Y Avg
-39304.63%
5Y Avg
-31311.91%
Market Cap
$76.84M
EBITDA Margin
-52.21%
TTM Avg
-73.45%
3Y Avg
-101.69%
5Y Avg
-126.11%
Market Cap
$77.73M
EBITDA Margin
-128297.25%
TTM Avg
-89238.38%
3Y Avg
-49477.43%
5Y Avg
-36037.89%
Market Cap
$76.50M
EBITDA Margin
-145368.18%
TTM Avg
-145368.18%
3Y Avg
-145368.18%
5Y Avg
-145368.18%
Market Cap
$76.10M
EBITDA Margin
1.51%
TTM Avg
-4.98%
3Y Avg
-8.74%
5Y Avg
-7.62%
Market Cap
$78.18M
EBITDA Margin
-2368.83%
TTM Avg
-2368.83%
3Y Avg
-1339.96%
5Y Avg
-991.53%
Market Cap
$75.18M
EBITDA Margin
-58.13%
TTM Avg
-62.55%
3Y Avg
-79.72%
5Y Avg
-85.39%
Market Cap
$79.61M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sera Prognostics, Inc. (SERA) | $77.15M | -43906.17% | -58684.18% | -39304.63% | -31311.91% |
| Outset Medical, Inc. (OM)vs › | $76.84M | -52.21% | -73.45% | -101.69% | -126.11% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $77.73M | -128297.25% | -89238.38% | -49477.43% | -36037.89% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $76.50M | -145368.18% | -145368.18% | -145368.18% | -145368.18% |
| Citius Oncology, Inc. (CTOR)vs › | $80.80M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $76.10M | 1.51% | -4.98% | -8.74% | -7.62% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.18M | -2368.83% | -2368.83% | -1339.96% | -991.53% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -58.13% | -62.55% | -79.72% | -85.39% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -4911.29% | -4911.29% | -4895.51% | -4835.22% |
Gross Margin
-102.5%
EBITDA Margin
-43906.2%
Operating Margin
-45066.7%
Net Margin
-47475.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -32806.67% |
| 2026-03-31 | -65478.57% |
| 2025-12-31 | -87100.00% |
| 2025-09-30 | -54606.25% |
| 2025-06-30 | -53429.41% |
| 2025-03-31 | -23773.68% |
| 2024-12-31 | -38383.33% |
| 2024-09-30 | -29865.52% |
| 2024-06-30 | -37687.50% |
| 2023-12-31 | -20819.51% |
| 2023-09-30 | -18657.14% |
| 2023-06-30 | -9047.97% |
| 2023-03-31 | -11092.00% |
| 2022-12-31 | -15715.38% |
| 2022-09-30 | -12626.44% |
| 2022-06-30 | -14821.79% |
| 2022-03-31 | -31934.21% |
| 2021-12-31 | -47700.00% |
| 2021-09-30 | -40460.87% |
| 2021-06-30 | -36020.00% |
| 2021-03-31 | -44800.00% |
| 2020-12-31 | -75866.67% |
| 2020-09-30 | -88160.00% |
| 2020-06-30 | -67516.67% |
| 2020-03-31 | -50812.50% |
